EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Mirum Pharmaceuticals, Inc. (MIRM) had EBIT Margin of -3.07% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$148.93M |
|
$-5.73M |
|
$28.26M |
|
$120.67M |
|
$153.50M |
|
$-4.57M |
|
$-0.40M |
|
$-4.96M |
|
$-4.96M |
|
$-5.73M |
|
$-5.73M |
|
$-5.73M |
|
$-5.73M |
|
$-4.57M |
|
$1.94M |
|
50.20M |
|
50.20M |
|
$-0.11 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$549.68M |
|
$1.86M |
|
$293.13M |
|
$842.81M |
|
$205.80M |
|
$309.80M |
|
$322.32M |
|
$528.12M |
|
$314.69M |
|
$53.77M |
|
$314.69M |
|
51.90M |
|
| Cash Flow Statement Financials | |
$55.83M |
|
$-23.95M |
|
$40.14M |
|
$222.93M |
|
$298.17M |
|
$75.24M |
|
$71.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.67 |
|
-- |
|
-- |
|
0.50 |
|
0.98 |
|
81.02% |
|
-3.07% |
|
|
EBIT Margin |
-3.07% |
-- |
|
-3.33% |
|
-3.85% |
|
$54.87M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
1.14 |
|
1.21 |
|
74.53 |
|
-1.82% |
|
-10.66% |
|
-0.68% |
|
-0.92% |
|
$6.06 |
|
$1.09 |
|
$1.11 |
|